Developer docs
API playgroundTry for free, no card

Search company profiles

BCAL Diagnostics

Full company profile

uuid0002ht4

Namestring
BCAL Diagnostics
Legal namestring
BCAL Diagnostics Limited
Company typeenum
Public
Founded yearint
2010
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSydney, Australia
HQ citystring
Sydney
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer diagnostic tests, blood-based diagnostics, lipidomic biomarker testing, breast cancer screening, clinical laboratory services
Industry6 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAKAFAJ
Breast Oncology
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code4 codes
  • Medical and Diagnostic Laboratories62151
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Cancer Diagnostics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Direct Diagnostic Test Sales
TypeOne Time License
Description

BCAL sells its diagnostic blood tests directly to patients through healthcare professional consultations. Tests are ordered by doctors and performed at approved blood collection centres. Revenue is generated on a per-test basis.

bcaldiagnostics.com
2Commercial Partnership Revenue
TypeTransaction Fee
Description

Revenue generated through commercial partnerships with pathology networks (Sonic Healthcare, Healius) for distribution of Avantect tests. Tests are priced at $1,495 per test or $1,995 for combined pancreatic and ovarian testing.

smallcaps.com.au
3BREASTEST plus Test Sales
TypeOne Time License
Description

First commercial product generating revenue at $300 per test, payable by patients at time of collection. Not currently covered by Medicare or private health insurance.

bcaldiagnostics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Pricing details3 tiers
1BREASTEST plus single test
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$300 per test, payable by EFTPOS at time of collection. Not currently covered by Medicare or private health insurance.

bcaldiagnostics.com
2Avantect single cancer test
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$1,495 per test for pancreatic or ovarian cancer detection.

smallcaps.com.au
3Avantect combined test
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$1,995 for combined pancreatic and ovarian cancer testing.

smallcaps.com.au
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 3 records shown
1BREASTEST plus™
Description

First-in-class blood test designed to be used alongside standard mammogram in breast cancer screening, particularly for women with dense breast tissue.

bcaldiagnostics.com
+2 more records
Core offering1 text field

BCAL Diagnostics develops and performs non-invasive blood-based diagnostic tests for cancer detection through its NATA-accredited laboratory in Sydney, Australia. Its flagship BREASTEST plus measures plasma lipid biomarkers using LC-MS/MS technology and a proprietary diagnostic algorithm to support breast cancer screening, particularly for women with dense breast tissue. The company also distributes the licensed Avantect epigenomics-based blood tests for early detection of pancreatic and ovarian cancer through pathology network partnerships.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 91% sensitivity in detecting breast cancer recurrence in clinical study of 450+ samples
+2 more records
Product overview1 text field

BCAL Diagnostics offers a portfolio of non-invasive blood tests for cancer detection. The core product is BREASTEST plus™, a lipidomic-based blood test using LC-MS/MS technology designed to complement mammography for breast cancer screening, particularly for women with dense breast tissue. The company has licensed Avantect® tests from ClearNote Health for pancreatic and ovarian cancer early detection, expanding beyond breast cancer. BREASTEST Monitor is under development for breast cancer recurrence monitoring. All tests are ordered through healthcare professionals and processed at BCAL's NATA-accredited commercial laboratory in Sydney.

Product and service4 records
1BREASTEST plus
CategoryCore product
Description

A first-in-class lipidomic blood test designed to be used alongside mammography in breast cancer screening, providing additional information for women with dense breasts to help rule out the presence of breast cancer. Uses Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) to measure lipid biomarkers in blood plasma and converts measurements to a test score via a proprietary diagnostic algorithm.

2BREASTEST Monitor
CategorySub-product
Description

A blood test to assist in evaluating women for local breast cancer recurrence after treatment. Demonstrated 91% sensitivity and 95% negative predictive value in clinical studies involving women aged 50 and above with previous breast cancer diagnosis.

3Avantect Pancreatic Cancer Test
CategoryLicensed product
Description

Early detection blood test for pancreatic cancer, licensed from ClearNote Health. Epigenomics-based test leveraging artificial intelligence and advanced genomic analysis. Priced at $1,495 per test.

4Avantect Ovarian Cancer Test
CategoryLicensed product
Description

Early detection blood test for ovarian cancer, licensed from ClearNote Health. Epigenomics-based test leveraging artificial intelligence and advanced genomic analysis. Priced at $1,495 per test or $1,995 for combined pancreatic and ovarian testing.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-26
Description

Partnership with Sonic Healthcare for commercial rollout of Avantect early detection blood tests for pancreatic and ovarian cancers. Tests available through Sonic Pathology collection centres across Australia.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-26
Description

Partnership with Healius for nationwide availability of Avantect pancreatic and ovarian cancer detection testing through Healius Pathology locations.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-09-18
Description

Exclusive licence partnership with US-based ClearNote Health Inc. providing access to Avantect pancreatic and ovarian cancer early detection blood tests across Australia and New Zealand. The epigenomics-based tests leverage artificial intelligence and advanced genomic analysis.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-27
Description

Initial partnership with Sonic Healthcare for pathology collection centre access to support commercial rollout of diagnostic tests.

5Cancer Care Associates
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-07-03
Description

Commercial partnership with Cancer Care Associates for distribution of cancer detection testing services.

bcaldiagnostics.com
6Precion
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-06-28
Description

US Product Development Agreement with Precion for product development activities in the United States market.

bcaldiagnostics.com
7Pancare Foundation
Strategic tierMinorTypeOthers
Description

Health economic evidence development collaboration with Pancare Foundation to support reimbursement discussions for pancreatic cancer tests.

smallcaps.com.au
Strategic tierMinorTypeOthers
Description

Health economic evidence collaboration with Pankind to support reimbursement discussions for pancreatic cancer testing.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Guardant Health is a leading US liquid biopsy company offering blood-based oncology diagnostics (Guardant360, Shield). Directly comparable as a blood-based cancer diagnostic company with proprietary assays and AI-driven algorithms.

2GRAIL
TypeDirect peer
Description

GRAIL develops the Galleri multi-cancer early-detection blood test, the most directly comparable liquid biopsy cancer screening product to BCAL's BREASTEST plus and planned multi-cancer test. Both target early-stage cancer detection via a single blood draw.

TypeDirect peer
Description

Natera offers Signatera, a blood-based ctDNA test for cancer recurrence monitoring, directly analogous to BCAL's BREASTEST Monitor. Both target minimal residual disease and recurrence detection via proprietary blood assays.

TypeDirect peer
Description

ANGLE plc has developed Parsortix, a liquid biopsy platform for capturing circulating tumour cells. Comparable as a UK-listed oncology diagnostics company developing blood-based cancer detection technologies.

TypeOthers
Description

Sonic Healthcare is a major Australian/global pathology operator that is both a distribution partner for BCAL's Avantect tests and a broader diagnostics incumbent. Included for completeness as a key channel partner and reference customer for Australian pathology scale.

TypeDirect peer
Description

VolitionRx develops Nu.Q blood-based cancer diagnostics using nucleosome quantification. Comparable as a small-cap blood-based cancer diagnostics company targeting multi-cancer detection with proprietary biomarker assays.

TypeBroad incumbent
Description

Quest Diagnostics is a major US clinical laboratory offering extensive cancer diagnostics including molecular and pathology testing. Comparable as a broad incumbent with significant cancer diagnostics infrastructure; BCAL board member Dr John Hurrell previously led development of 70+ molecular diagnostics tests at Quest's Focus Diagnostics subsidiary.

8Mainz Biomed
TypeEmerging player
Description

Mainz Biomed is an emerging molecular genetics diagnostics company developing ColoAlert and PancAlert - blood/stool-based cancer screening tests. Comparable as a small-cap early-stage cancer diagnostics company expanding its test portfolio.

TypeDirect peer
Description

Pacific Edge (NZX/ASX-listed) commercialises Cxbladder, a urine-based cancer diagnostic test. Highly comparable as a NZX/ASX-listed cancer diagnostics company with a similar early-commercialisation profile; BCAL board member David Darling was previously its CEO.

TypeDirect peer
Description

Exact Sciences commercialises Cologuard and Oncotype DX cancer screening/diagnostic tests. Comparable as a publicly-listed cancer diagnostics company with reimbursed blood/stool-based screening products at scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BCAL Diagnostics

Cancer Diagnosticsbcaldiagnostics.com

BCAL Diagnostics firmographics

Firmographics
Name
BCAL Diagnostics
Legal name
BCAL Diagnostics Limited
Website
https://bcaldiagnostics.com
Company type
Public
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

BCAL Diagnostics industry classification

Industry
Product category
Cancer Diagnostics
NAICS
Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAKAFAJ
Breast Oncology
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Cancer diagnostic tests
  • Blood-based diagnostics
  • Lipidomic biomarker testing
  • Breast cancer screening
  • Clinical laboratory services

Where BCAL Diagnostics is headquartered

Location

Headquarters

HQ city
Sydney
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

BCAL Diagnostics business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Direct Diagnostic Test Sales: BCAL sells its diagnostic blood tests directly to patients through healthcare professional consultations. Tests are ordered by doctors and performed at approved blood collection centres. Revenue is generated on a per-test basis.
  2. Commercial Partnership Revenue: Revenue generated through commercial partnerships with pathology networks (Sonic Healthcare, Healius) for distribution of Avantect tests. Tests are priced at $1,495 per test or $1,995 for combined pancreatic and ovarian testing.
  3. BREASTEST plus Test Sales: First commercial product generating revenue at $300 per test, payable by patients at time of collection. Not currently covered by Medicare or private health insurance.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goBREASTEST plus single test
Unit PricingPay-as-you-goAvantect single cancer test
Unit PricingPay-as-you-goAvantect combined test

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

BCAL Diagnostics product offering

Product offering

Core offering

BCAL Diagnostics develops and performs non-invasive blood-based diagnostic tests for cancer detection through its NATA-accredited laboratory in Sydney, Australia. Its flagship BREASTEST plus measures plasma lipid biomarkers using LC-MS/MS technology and a proprietary diagnostic algorithm to support breast cancer screening, particularly for women with dense breast tissue. The company also distributes the licensed Avantect epigenomics-based blood tests for early detection of pancreatic and ovarian cancer through pathology network partnerships.

Product overview

BCAL Diagnostics offers a portfolio of non-invasive blood tests for cancer detection. The core product is BREASTEST plus™, a lipidomic-based blood test using LC-MS/MS technology designed to complement mammography for breast cancer screening, particularly for women with dense breast tissue. The company has licensed Avantect® tests from ClearNote Health for pancreatic and ovarian cancer early detection, expanding beyond breast cancer. BREASTEST Monitor is under development for breast cancer recurrence monitoring. All tests are ordered through healthcare professionals and processed at BCAL's NATA-accredited commercial laboratory in Sydney.

Differentiator

Problem solved

Functional benefit

Brands

  • BREASTEST plus™: First-in-class blood test designed to be used alongside standard mammogram in breast cancer screening, particularly for women with dense breast tissue.
  • BREASTEST Monitor
  • Avantect®

Products and services

  • BREASTEST plus A first-in-class lipidomic blood test designed to be used alongside mammography in breast cancer screening, providing additional information for women with dense breasts to help rule out the presence of breast cancer. Uses Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) to measure lipid biomarkers in blood plasma and converts measurements to a test score via a proprietary diagnostic algorithm.
  • BREASTEST Monitor A blood test to assist in evaluating women for local breast cancer recurrence after treatment. Demonstrated 91% sensitivity and 95% negative predictive value in clinical studies involving women aged 50 and above with previous breast cancer diagnosis.
  • Avantect Pancreatic Cancer Test Early detection blood test for pancreatic cancer, licensed from ClearNote Health. Epigenomics-based test leveraging artificial intelligence and advanced genomic analysis. Priced at $1,495 per test.
  • Avantect Ovarian Cancer Test Early detection blood test for ovarian cancer, licensed from ClearNote Health. Epigenomics-based test leveraging artificial intelligence and advanced genomic analysis. Priced at $1,495 per test or $1,995 for combined pancreatic and ovarian testing.

Quantifiable outcome

  • 91% sensitivity in detecting breast cancer recurrence in clinical study of 450+ samples
  • +2 more outcomes

Companies that use BCAL Diagnostics

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

BCAL Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

BCAL Diagnostics partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Sonic HealthcarecoreChannel Partner/ Reseller/ Distributor · 26 March 2026Partnership with Sonic Healthcare for commercial rollout of Avantect early detection blood tests for pancreatic and ovarian cancers. Tests available through Sonic Pathology collection centres across Australia.
  • HealiuscoreChannel Partner/ Reseller/ Distributor · 26 March 2026Partnership with Healius for nationwide availability of Avantect pancreatic and ovarian cancer detection testing through Healius Pathology locations.
  • ClearNote Health Inc.coreTechnology or Integration · 18 September 2025Exclusive licence partnership with US-based ClearNote Health Inc. providing access to Avantect pancreatic and ovarian cancer early detection blood tests across Australia and New Zealand. The epigenomics-based tests leverage artificial intelligence and advanced genomic analysis.
  • Sonic Healthcare (Initial Partnership)coreChannel Partner/ Reseller/ Distributor · 27 August 2025Initial partnership with Sonic Healthcare for pathology collection centre access to support commercial rollout of diagnostic tests.
  • Cancer Care AssociatesminorChannel Partner/ Reseller/ Distributor · 3 July 2025Commercial partnership with Cancer Care Associates for distribution of cancer detection testing services.
  • PrecionminorStrategic or Co-development Partner · 28 June 2022US Product Development Agreement with Precion for product development activities in the United States market.
  • Pancare FoundationminorOthersHealth economic evidence development collaboration with Pancare Foundation to support reimbursement discussions for pancreatic cancer tests.
  • PankindminorOthersHealth economic evidence collaboration with Pankind to support reimbursement discussions for pancreatic cancer testing.

Scale indicators9 records

Recent moves7 records

Expansion highlights7 records

BCAL Diagnostics competitors and assessment

Company assessment

Direct peers

  • Guardant Health: Guardant Health is a leading US liquid biopsy company offering blood-based oncology diagnostics (Guardant360, Shield). Directly comparable as a blood-based cancer diagnostic company with proprietary assays and AI-driven algorithms.
  • GRAIL: GRAIL develops the Galleri multi-cancer early-detection blood test, the most directly comparable liquid biopsy cancer screening product to BCAL's BREASTEST plus and planned multi-cancer test. Both target early-stage cancer detection via a single blood draw.
  • Natera: Natera offers Signatera, a blood-based ctDNA test for cancer recurrence monitoring, directly analogous to BCAL's BREASTEST Monitor. Both target minimal residual disease and recurrence detection via proprietary blood assays.
  • ANGLE plc: ANGLE plc has developed Parsortix, a liquid biopsy platform for capturing circulating tumour cells. Comparable as a UK-listed oncology diagnostics company developing blood-based cancer detection technologies.
  • VolitionRx: VolitionRx develops Nu.Q blood-based cancer diagnostics using nucleosome quantification. Comparable as a small-cap blood-based cancer diagnostics company targeting multi-cancer detection with proprietary biomarker assays.
  • Pacific Edge: Pacific Edge (NZX/ASX-listed) commercialises Cxbladder, a urine-based cancer diagnostic test. Highly comparable as a NZX/ASX-listed cancer diagnostics company with a similar early-commercialisation profile; BCAL board member David Darling was previously its CEO.
  • Exact Sciences: Exact Sciences commercialises Cologuard and Oncotype DX cancer screening/diagnostic tests. Comparable as a publicly-listed cancer diagnostics company with reimbursed blood/stool-based screening products at scale.

Others

  • Sonic Healthcare: Sonic Healthcare is a major Australian/global pathology operator that is both a distribution partner for BCAL's Avantect tests and a broader diagnostics incumbent. Included for completeness as a key channel partner and reference customer for Australian pathology scale.

Broad incumbents

  • Quest Diagnostics: Quest Diagnostics is a major US clinical laboratory offering extensive cancer diagnostics including molecular and pathology testing. Comparable as a broad incumbent with significant cancer diagnostics infrastructure; BCAL board member Dr John Hurrell previously led development of 70+ molecular diagnostics tests at Quest's Focus Diagnostics subsidiary.

Emerging players

  • Mainz Biomed: Mainz Biomed is an emerging molecular genetics diagnostics company developing ColoAlert and PancAlert - blood/stool-based cancer screening tests. Comparable as a small-cap early-stage cancer diagnostics company expanding its test portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

BCAL Diagnostics social profiles

Digital presence

BCAL Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BCAL Diagnostics leadership team

Management profile

Number of profiles

Profiles12 records

BCAL Diagnostics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BCAL Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BCAL Diagnostics

What does BCAL Diagnostics do?

BCAL Diagnostics develops and performs non-invasive blood-based diagnostic tests for cancer detection through its NATA-accredited laboratory in Sydney, Australia. Its flagship BREASTEST plus measures plasma lipid biomarkers using LC-MS/MS technology and a proprietary diagnostic algorithm to support breast cancer screening, particularly for women with dense breast tissue. The company also distributes the licensed Avantect epigenomics-based blood tests for early detection of pancreatic and ovarian cancer through pathology network partnerships.

Is BCAL Diagnostics a public or private company?

BCAL Diagnostics is a public company. It is classified as public and is currently operating.

When was BCAL Diagnostics founded?

BCAL Diagnostics was founded in 2010. It employs 11 to 50 people.

Where is BCAL Diagnostics based?

BCAL Diagnostics is headquartered in Sydney, Australia, in the Oceania region.

How does BCAL Diagnostics make money?

Three revenue lines are on record. Direct Diagnostic Test Sales are the primary driver. The others are commercial Partnership Revenue and BREASTEST plus Test Sales.

Who are BCAL Diagnostics's main competitors?

Direct peers on record are Guardant Health, GRAIL, Natera, ANGLE plc, VolitionRx, Pacific Edge and Exact Sciences. Sonic Healthcare is listed as an others. Quest Diagnostics is listed as a broad incumbent. Mainz Biomed is listed as an emerging player.

Does BCAL Diagnostics have an API?

No public API is recorded for BCAL Diagnostics.

What industry is BCAL Diagnostics in?

BCAL Diagnostics's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays. Its NAICS code is 62151 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AInvestGenetic Signatures - Received a request from BCAL Diagnostics for directors of GSS to call and arrange general meeting of shareholdersBCAL Diagnostics requested a general meeting of Genetic Signatures shareholders after acquiring a 10.2% stake for $1,390,119. The investment, made through 23,173,644 shares at 6.0 cents, aims to establish a second diagnostics pillar in infectious disease. Further details on the meeting agenda have not been disclosed.KalkineBCAL Diagnostics (ASX:BDX) Increases Genetic Signatures Holding as It Targets Broader Diagnostic PlatformBCAL Diagnostics increased its stake in Genetic Signatures by acquiring 18.75 million shares for $1.5m, raising its ownership to approximately 18.46%. The investment aims to broaden BCAL's diagnostic platform into infectious disease applications, complementing its existing cancer detection portfolio.AInvestBCAL Can't Touch $2.4 Million Because It's Not Sure It Can Make the SharesBCAL Diagnostics cannot access $2.4 million of its committed convertible debt facility due to uncertainty regarding shareholder approval for the necessary share issuances under ASX Listing Rule 7.1. The company has already utilized 15% of its annual share placement capacity, preventing the conversion of existing notes and blocking further draws until a general meeting grants permission. This regulatory bottleneck highlights a structural conflict where the mechanism intended to provide funding is consuming the very capacity required for its execution.NewsnReleasesBCAL Diagnostics acquires 10.2% stake in Genetic Signatures for $1.4 millionBCAL Diagnostics Ltd., an Australian healthcare company focused on early cancer detection, has acquired a 10.2% stake in Genetic Signatures Ltd. for approximately $1.39 million in an all-cash transaction, purchasing 23,173,644 shares at 6.0 cents per share. The investment positions BCAL to leverage Genetic Signatures' established commercial operations, FDA 510(k) clearance, and international market access across Asia Pacific, Europe, the Middle East, Africa, the U.S., and the U.K. for expansion beyond oncology into infectious disease diagnostics. Both companies are listed on the Australian Securities Exchange, with Genetic Signatures remaining independent while BCAL gains exposure to an additional diagnostics pillar.KalkineBCAL Diagnostics Secures $4.9 Million Convertible Note Top-Up and $1.4 Million R&D Tax Offset to Fund FY2027 Cancer Detection PipelineBCAL Diagnostics Limited secured an additional $4.9 million under its existing convertible note facility and expects a $1.4 million R&D tax offset tranche to fund operations through FY2027. This combined funding supports the commercialisation of its blood-based cancer detection portfolio, including BREASTESTplus and the Avantect suite licensed from ClearNote Health Inc., without requiring dilutive equity raises.YahooBCAL Diagnostics develops blood test to evaluate breast cancerAustralian healthcare company BCAL Diagnostics is developing the BREASTEST Monitor blood test to assist in evaluating women for local breast cancer recurrence after treatment, demonstrating 91% sensitivity and 95% negative predictive value in a study of over 450 samples involving women aged 50 and above with previous breast cancer diagnosis. The company aims to introduce the test as an adjunct to existing imaging methods like mammography and MRI, with further clinical validation studies planned before commercial launch. BCAL Diagnostics also holds an exclusive licence with ClearNote Health for distribution of certain blood tests in Australia and New Zealand.Medical Device NetworkBCAL Diagnostics develops blood test to evaluate breast cancerAustralian healthcare company BCAL Diagnostics is developing the BREASTEST Monitor blood test to assist in evaluating women for local breast cancer recurrence after treatment. In a clinical study involving 100 held-out samples, the test demonstrated 91% sensitivity, correctly identifying 20 out of 23 confirmed recurrence cases with a negative predictive value of 95%. The company plans additional clinical validation studies before commercial launch and aims to introduce the test initially as an adjunct to imaging, with further development for standalone use.geelongadvertiserIt’s America or bust as BCAL eyes fast track US routeBCAL Diagnostics has partnered with Sonic Healthcare to validate and optimize its Breastest plus breast cancer assay at a US lab, aiming for a rapid entry into the American market. The agreement allows BCAL to leverage Sonic's infrastructure for CLIA-certified testing, with an option for Sonic to license the test following validation. This strategic move targets the US diagnostics market, which is projected to be worth US$4.53 billion by 2033.KalkineBCAL Diagnostics (ASX:BDX) Shares Rally on Expansion of National Cancer Test AccessBCAL Diagnostics shares increased by 16.88% following an update about expanding access to its cancer detection tests across Australia through integration with healthcare software, telehealth services, and new clinics. The company announced the planned launch of its multi-cancer early detection test in June 2026 and the establishment of a specialized clinic in Sydney.